In the Media
Are you looking for the latest media coverage of the BioMed X Institute, its research projects and people behind the innovation model? Here you will find the latest clippings – hot off the press!
Amazon and Big Pharma Unite to Propel AI Innovation in Therapeutics
BioSpace
Four leading pharmaceutical companies partnered with Amazon Web Services and Israel Biotech Fund to launch AION Labs, an innovative space that will allow drug developers to harness artificial intelligence technologies and computational science to solve therapeutic challenges.
AWS and pharma heavyweights join forces on AI-based drug discovery lab
Drug Discovery & Development
The goal of using artificial intelligence to transform drug discovery and development may not be novel. But a new alliance is unique in both the stature of companies belonging to it and its choice of an innovation model.
Big Pharma companies join hands with Amazon on new Israel-based AI incubator
Endpoints News
What do Merck, Pfizer, AstraZeneca and Teva have in common with Amazon? As of Wednesday, they’re all joining forces with the Israel Biotech Fund to launch a new incubator for startups walking the line between AI and drug development — and they’re gearing up to make some big investments.
Eine Gemeinschaft der Willigen – Standortakteure aus Heidelberg im Gespräch
GoingPublic.de
Die Plattform Life Sciences führte eine Gesprächsrunde mit den wichtigen Vertretern dieser neuen Entwicklungen in der Rhein-Neckar-Region. Unter dem Fokusthema „Translation“ haben sich dazu hybrid getroffen: Dr. Julia Schaft (BioRN), Dr. Christian Tidona (BioMed X), Dr. Johannes Frühauf (BioLabs, LabCentral), Dr. Siegfried Bialojan (ehemaliger EY-Experte Life Sciences), Dr. Thomas Hanke (Evotec), Dr. Friedrich Reinhard (Evotec; „Expert in Residence“ beLAB2122 in…
Professionelle Translation in Heidelberg – Das BioMed X Institut
Deutsche Biotechnologietage 2021
rotz des technologischen Fortschritts in der medizinischen Grundlagenforschung und des stetig wachsenden Wissens über menschliche Krankheiten, ist die Translation von Forschungsergebnissen in therapeutische Fortschritte immer noch ineffizient.
BioMed X, Janssen Begin Autoimmunity and Drug Delivery Research
Pharma Advancement
German independent research institute BioMed X has initiated two new research projects with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The collaboration aims to address two challenging new research areas.
BioMed X Institute to launch autoimmunity and drug delivery research programs
BioSpectrum Asia Edition
New research groups in Heidelberg to examine protective tissue factors in autoimmune diseases and the translocation of complex macromolecules across the intestinal epithelial barrier in collaboration with Janssen.
BioMed X Institute Today Announces Two New Research Groups in Autoimmunity and Drug Delivery in Collaboration with Janssen
Pharmiweb
BioMed X Institute to start two new research programs in the field of autoimmune diseases and drug delivery. New research groups in Heidelberg to examine protective tissue factors in autoimmune diseases and the translocation of complex macromolecules across the intestinal epithelial barrier.
BioMed X Institute to launch autoimmunity and drug delivery research programs
BioSpectrum
New research groups in Heidelberg to examine protective tissue factors in autoimmune diseases and the translocation of complex macromolecules across the intestinal epithelial barrier in collaboration with Janssen
BioMed X expands research partnership with Merck KGaA
Pharmaceutical Commerce
BioMed X, an independent research institute, revealed the start of its eighth joint research program with Merck KGaA, Darmstadt, Germany. The new program will dive into the role of extrachromosomal DNA in cancer and it will complement the research of two ongoing oncology programs at BioMed X in the fields of DNA damage response and RNA splicing.